Chimeric murine-human monoclonal antibody directed against the CD20 surface protein found on normal and malignant B lymphocytes. Contains murine light and heavy-chain variable regions and γ1 heavy-chain and κ light chain human constant regions. Composed of 2 heavy chains of 451 amino acids and 2 light chains of 213 amino acids; approx mol wt 145 kDa. Biological response modifier that depletes mature B cells from blood and tissue. Prepn: D. R. Anderson et al., WO 9411026; eidem, US 5736137 (1994, 1998 both to IDEC); M. E. Reff et al., Blood 83, 435 (1994). HPLC determn of product purity: K. G. Moorhouse et al., J. Pharm. Biomed. Anal. 16, 593 (1997). Clinical pharmacokinetics: N. L. Berinstein et al., Ann. Oncol. 9, 995 (1998). Review of pharmacology and clinical experience in non-Hodgkin's lymphoma: S. V. Onrust et al., Drugs 58, 79-88 (1999); A. Molina, Annu. Rev. Med. 59, 237-250 (2008); in rheumatoid arthritis: A. A. Schuna, Pharmacotherapy 27, 1702-1710 (2007). Clinical effect on immunocompetency in patients with autoimmune disease: R. J. Looney et al., Arthritis Rheum. 58, 5-14 (2008).
Antineoplastic; anti-inflammatory.
Antineoplastic; Monoclonal Antibodies; Anti-inflammatory (Biological Response Modifier)